Sustanon Dosages and Administration
Originally designed and intended for clinical and medical use especially in Testosterone replacement therapy (TRT), medical Sustanon dosages average at 250mg administration every 3 weeks, and are normally adjusted according to individual needs as the physician deems necessary.
In the athletic and bodybuilding circles, most beginner Sustanon dosages begin at around 300 – 500mg weekly. Normally there is no need to increase Sustanon dosages beyond this range especially when utilized with other compounds. Intermediate users often venture into the realm of 500 – 750mg per week, often when Sustanon is used alone. Intermediate users will often still remain in the 500mg weekly range when utilizing other compounds with it. Advanced users are known to rise as high as 750 – 1000mg per week, but again, this is usually only when Sustanon is used alone and not with other anabolic steroids.
Another common option is the use of TRT level dosages of Sustanon to merely provide a base level of the hormone in order to facilitate essential biological functions while other stronger compounds are emphasized to promote anabolic effects. In this case, users will often utilize Sustanon at 100 – 250mg per week and rely on other compounds at higher dosages to experience performance and physique benefits.
Sustanon 250 is not recommended for females due to its strong androgenic nature, and females are therefore advised to look elsewhere into less potent androgens that can be used for performance and physique enhancement.
Potential Sustanon side effects include all of those that are typical of Testosterone itself, as after all Sustanon is a direct Testosterone product.
The first area of concern are Estrogenic side effects due to the nature of Testosterone being an aromatizable anabolic steroid. It expresses affinity for the aromatase enzyme, which is responsible for aromatization (or conversion) of Testosterone into Estrogen. Estrogenic side effects include water retention and bloating, blood pressure elevations (as a result of the water retention), increased possible fat retention/gain, and gynecomastia. These are all dose and sensitivity dependent, of course, and higher dosages of Sustanon will increase the frequency and severity of these Sustanon side effects. In order to mitigate these Sustanon side effects, the use of an aromatase inhibitor and/or an Estrogen blocker, such as SERM like Nolvadex (Tamoxifen Citrate), will be necessary. Further research into the differences between aromatase inhibitors (AIs) and SERMs (Selective Estrogen Receptor Modulators) should be researched by the user in order to fully understand the differences.
Androgenic side effects are also a concern, as Testosterone will readily reduce into Dihydrotestosterone (DHT) in various tissues throughout the body. This creates an overall increase in androgenic side effects, as DHT is a much stronger androgen than Testosterone itself is. Although Testosterone itself possesses moderate androgenic strength, the problem lies in DHT, which is a much more powerful androgen. Androgenic side effects include: increased sebum secretion (oily skin), increased bouts of acne (linked to increased sebum secretion), bodily and facial hair growth, and the increased risk of triggering Male Pattern Baldness (MPB) in individuals that possess the genetic trait required for the condition to manifest itself. These Sustanon side effects can be mitigated through the use of 5-alpha reductase inhibitors, and topical DHT antagonists, such as Nizoral.
Virilization (masculinizing) side effects is a big issue with strong androgens such as Testosterone, and this is why it is not recommended for use in casual female users. Virilization includes side effects such as bodily and facial hair growth, deepening of the voice, clitoral enlanrgement, and menstrual irregularities.
Hepatotoxicity and liver issues are not a concern with the use of Sustanon 250 or any injectable Testosterone product.
Testosterone has demonstrable negative effects on the cardiovascular system, most notably on the negative alteration of cholesterol profiles. Testosterone use alone promotes a low to moderate reduction of HDL (‘good’ cholesterol), but studies have demonstrated even worse alterations when it is combined with the use of aromatase inhibitors, causing an additional increase in LDL (‘bad’ cholesterol) and even larger decreases in HDL.
Being an anabolic steroid, Testosterone will initiate disruption, suppression and shutdown of endogenous Testosterone production, especially at bodybuilding dosages.
Sustanon Cycles and Uses
The intention of Sustanon 250 is to, as a whole, provide an initial spike in blood plasma levels of Testosterone within 24 – 48 hours following administration. Following this, blood levels should remain elevated for a period of 21 days as a result of the larger Testosterone esters contained in the blend. The idea here, as previously mentioned, was to utilize Sustanon almost exclusively in the treatment of Testosterone replacement therapy. This should be kept in mind when anyone is willing to run Sustanon cycles. The first indication that Sustanon’s half-life characteristics should give is the fact that Sustanon cycles need to be run for much longer periods as a result, typically 10 – 14 weeks. Even 10 week Sustanon cycles are regarded as being on the short end.
Sustanon cycles often involve the use of Sustanon-only, especially in the case of first-time and beginner cycles. Being a Testosterone product, Sustanon can and is also used as a base compound in a cycle containing other products. Beginner cycles can also include at least one other compound, typically with the intention of mass and strength gaining, and bulking. An example here would be Sustanon 250 utilized for 12 weeks, with Dianabol (Methandrostenolone) as a kickstarting compound during the first 4 – 6 weeks of the cycle. Nandrolone Decanoate (Deca-Duarbolin) is also commonly combined with Sustanon cycles, and tends to combine especially well with it due to its longer half-life, and is suitable in longer cycle lengths of 12 weeks or longer.
- Ramamani A, Aruldhas MM, Govindarajulu P. Differential response of rat skeletal muscle glycogen metabolism to testosterone and estradiol. Can J Physiol Pharmacol. 1999 Apr;77(4):300-4.
- Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol 20:233-237.
- High-density lipoprotein choilesterol is not decreased if an aromatizable androgen is administered. Friedl K, Hannan C et al. Metabolism 39(1) 1990.
- Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L. et al. Am J Physiol Endocrinol Metab 281:E1172-81, 2001.
- Product data sheet: Sustanon 250. August 31, 2001. Pharmaco (N.Z.) LTD Auckland New Zealand.